Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model

Mark J. Bailey, James Duehr, Harrison Dulin, Felix Broecker, Julia A. Brown, Fortuna O. Arumemi, Maria C. Bermúdez González, Victor H. Leyva-Grado, Matthew J. Evans, Viviana Simon, Jean K. Lim, Florian Krammer, Rong Hai, Peter Palese and Gene S. Tan ()
Additional contact information
Mark J. Bailey: Icahn School of Medicine at Mount Sinai
James Duehr: Icahn School of Medicine at Mount Sinai
Harrison Dulin: University of California Riverside
Felix Broecker: Icahn School of Medicine at Mount Sinai
Julia A. Brown: Icahn School of Medicine at Mount Sinai
Fortuna O. Arumemi: The J. Craig Venter Institute
Maria C. Bermúdez González: Icahn School of Medicine at Mount Sinai
Victor H. Leyva-Grado: Icahn School of Medicine at Mount Sinai
Matthew J. Evans: Icahn School of Medicine at Mount Sinai
Viviana Simon: Icahn School of Medicine at Mount Sinai
Jean K. Lim: Icahn School of Medicine at Mount Sinai
Florian Krammer: Icahn School of Medicine at Mount Sinai
Rong Hai: University of California Riverside
Peter Palese: Icahn School of Medicine at Mount Sinai
Gene S. Tan: The J. Craig Venter Institute

Nature Communications, 2018, vol. 9, issue 1, 1-11

Abstract: Abstract Zika virus is a mosquito-borne flavivirus closely related to dengue virus that can cause severe disease in humans, including microcephaly in newborns and Guillain-Barré syndrome in adults. Specific treatments and vaccines for Zika virus are not currently available. Here, we isolate and characterize four monoclonal antibodies (mAbs) from an infected patient that target the non-structural protein NS1. We show that while these antibodies are non-neutralizing, NS1-specific mAbs can engage FcγR without inducing antibody dependent enhancement (ADE) of infection in vitro. Moreover, we demonstrate that mAb AA12 has protective efficacy against lethal challenges of African and Asian lineage strains of Zika virus in Stat2–/– mice. Protection is Fc-dependent, as a mutated antibody unable to activate known Fc effector functions or complement is not protective in vivo. This study highlights the importance of the ZIKV NS1 protein as a potential vaccine antigen.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-018-07008-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07008-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-07008-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().